ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.
Gufic delivered record Q4 FY26 revenue of ₹252cr with EBITDA margins expanding to 17.7%. Management is pivoting to an IP-led international model and scaling the new Indore facility.
Gufic delivered its strongest ever quarter in Q4FY26, driven by Indore facility break-even and a strategic shift in the international business model towards holding its own marketing authorizations.
Gufic Biosciences reported Q4 FY26 revenue of ₹252.1 cr and PAT of ₹20.5 cr. Strategy focuses on scaling the Indore facility and transitioning to an IP-owned international model.